NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $10.96 -0.15 (-1.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.99 +0.03 (+0.26%) As of 08/1/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pharming Group Stock (NASDAQ:PHAR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharming Group alerts:Sign Up Key Stats Today's Range$10.55▼$11.2950-Day Range$9.50▼$12.1652-Week Range$6.73▼$12.61Volume23,035 shsAverage Volume4,439 shsMarket Capitalization$750.87 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingBuy Company Overview Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScorePHAR MarketRank™: Pharming Group scored higher than 60% of companies evaluated by MarketBeat, and ranked 385th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPharming Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePharming Group has received no research coverage in the past 90 days.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pharming Group are expected to grow in the coming year, from ($0.20) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is -84.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is -84.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Pharming Group have been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 26.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Pharming Group have been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 26.67%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.84 News SentimentPharming Group has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pharming Group this week, compared to 3 articles on an average week.Search Interest5 people have searched for PHAR on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.07% of the stock of Pharming Group is held by insiders.Percentage Held by InstitutionsOnly 0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAR Stock News HeadlinesPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)1 hour ago | finance.yahoo.comPharming Group (NASDAQ:PHAR) Shares Gap Up Following Better-Than-Expected EarningsAugust 2 at 2:17 AM | americanbankingnews.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 2 at 2:00 AM | Banyan Hill Publishing (Ad)Pharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptAugust 1 at 4:17 PM | seekingalpha.comPharming Group N.V. 2025 Q2 - Results - Earnings Call PresentationAugust 1 at 2:57 PM | seekingalpha.comPharming Group reports second quarter and first half 2025 financial results and provides business updateJuly 31 at 4:58 AM | finance.yahoo.comHigh Growth Tech Stocks To Watch In Europe July 2025July 29, 2025 | finance.yahoo.comPharming Group N.V. (PHGUF) stock price, news, quote & history ...July 11, 2025 | sg.finance.yahoo.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $10.06 at the start of the year. Since then, PHAR stock has increased by 8.9% and is now trading at $10.96. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) posted its quarterly earnings data on Thursday, July, 31st. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. The firm earned $93.20 million during the quarter, compared to analysts' expectations of $70.36 million. Pharming Group had a negative trailing twelve-month return on equity of 3.38% and a negative net margin of 2.19%. Read the conference call transcript. Who are Pharming Group's major shareholders? Pharming Group's top institutional investors include Silverberg Bernstein Capital Management LLC (0.08%). How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Sunworks (SUNW), Applied DNA Sciences (APDN), AstraZeneca (AZN) and Costco Wholesale (COST). Company Calendar Last Earnings7/31/2025Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Price Target for Pharming Group$30.00 High Price Target$39.00 Low Price Target$14.00 Potential Upside/Downside+173.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.84 million Net Margins-2.19% Pretax Margin-1.14% Return on Equity-3.38% Return on Assets-1.82% Debt Debt-to-Equity Ratio0.39 Current Ratio2.76 Quick Ratio2.00 Sales & Book Value Annual Sales$297.20 million Price / Sales2.53 Cash Flow$0.07 per share Price / Cash Flow149.88 Book Value$3.25 per share Price / Book3.37Miscellaneous Outstanding Shares68,510,000Free Float67,097,000Market Cap$750.87 million OptionableNot Optionable Beta0.02 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PHAR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.